Immuneering
Immuneering Corp
Immuneering Corporation is a clinical-stage biopharmaceutical company that utilizes computational biology and its proprietary Disease Cancelling Technology platform to discover and develop targeted therapies for cancer. Having transitioned from a service-based model, the company now focuses on advancing its own pipeline of novel drugs designed to offer improved efficacy and tolerability for patients with difficult-to-treat diseases.
Products & Team
Atebimetinib (IMM-1-104)
Atebimetinib is the company's lead product candidate, an oral, once-daily deep cyclic inhibitor of the MEK kinase within the MAPK signaling pathway. It is being developed for the treatment of tumors driven by this pathway, such as pancreatic cancer, with a design intended to provide improved durability and tolerability over existing therapies.
Atebimetinib aims to solve the challenge of treating MAPK pathway-driven cancers by providing a more effective and better-tolerated therapeutic option, potentially reducing the severe side effects often associated with traditional cancer treatments.
Patients with advanced cancers often face treatments with limited efficacy, the development of drug resistance, and significant, often debilitating, side effects that impact their quality of life. Immuneering's therapies aim to address these issues by being more selective and better tolerated.